Log in
E-mail
Password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
Settings
Settings
Dynamic quotes 
OFFON

MarketScreener Homepage  >  Equities  >  Nasdaq  >  Ultragenyx Pharmaceutical Inc    RARE

ULTRAGENYX PHARMACEUTICAL INC

(RARE)
  Report  
SummaryQuotesChartsNewsRatingsCalendarCompanyFinancialsConsensusRevisions 
Income Statement Evolution
Annual Income Statement Data
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Sales0,132,6151,597,3211352
EBITDA-245-323-352-386-257-216
Operating profit (EBIT)-248-329-371-387-284-175
Pre-Tax Profit (EBT)-246-318-197-376-282-187
Net income-246-302-198-377-281-186
P/E ratio-11,3-6,51-11,0-8,27-11,9-18,5
EPS ( $ )-6,21-7,12-3,97-6,92-4,82-3,10
Dividend per Share ( $ )------
Yield------
Reference price ( $ )70.3146.3843.4857.1857.1857.18
Announcement Date02/16/2017
09:05pm
02/20/2018
09:46pm
02/19/2019
09:01pm
---
Finances - Leverage
Actuals in M $ Estimates in M $
Fiscal Period December 201620172018201920202021
Debt------
Finance380244460355354223
Operating income (EBITDA)-245-323-352-386-257-216
Leverage
(Debt/EBITDA)
------
Capital Expenditure10,22,794,0812,320,013,2
Book Value Per Share (BVPS)11,8 $8,68 $12,0 $9,87 $8,79 $6,98 $
Cash Flow per Share-4,07 $-5,98 $-5,84 $-5,31 $-2,77 $-1,82 $
Announcement Date02/16/2017
09:05pm
02/20/2018
09:46pm
02/19/2019
09:01pm
---
Balance Sheet Analysis
Assessed data source :
© 2019 Thomson Reuters
Financial Ratios

Size 2019e 2020e
Capitalization 3 286 M$ -
Entreprise Value (EV) 2 932 M$ 2 932 M$
Valuation 2019e 2020e
P/E ratio (Price / EPS)
Capitalization / Revenue 33,8x 15,6x
EV / Revenue 30,1x 13,9x
EV / EBITDA -7,59x -11,4x
Yield (DPS / Price) - -
Price to book (Price / BVPS) 5,79x 6,50x
Profitability 2019e 2020e
Operating Margin (EBIT / Sales) -398% -134%
operating Leverage (Delta EBIT / Delta Sales) - 0,23x
Net Margin (Net Profit / Revenue) -388% -133%
ROA (Net Profit / Asset) -60,2% -57,1%
ROE (Net Profit / Equities) -66,0% -62,7%
Rate of Dividend - -
Balance Sheet Analysis 2019e 2020e
CAPEX / Sales   12,6% 9,46%
Cash Flow / Sales -314% -75,5%
Capital Intensity (Assets / Sales) 6,45x 2,33x
Financial Leverage (Net Debt / EBITDA) 0,92x 1,38x
EPS & Dividend